Suscribirse

Electrocardiography Screening for Cardiotoxicity after Modified Vaccinia Ankara Vaccination - 12/08/11

Doi : 10.1016/j.amjmed.2008.07.025 
Junko Sano, MD a, Bernard R. Chaitman, MD a, , Jason Swindle, MPH b, Sharon E. Frey, MD c
a The Saint Louis University School of Medicine, Department of Medicine, Division of Cardiology, St Louis, Mo 
b The Saint Louis University School of Medicine, Department of Medicine, Saint Louis University Center for Outcomes Research, St Louis, Mo 
c The Saint Louis University School of Medicine, Department of Medicine, Division of Infectious Disease, St Louis, Mo 

Requests for reprints should be addressed to Bernard R. Chaitman, MD, Saint Louis University School of Medicine, Department of Internal Medicine, Division of Cardiology, 1034 S. Brentwood Blvd, Suite 1550, St Louis, MO 63117

Abstract

Background

Symptomatic myopericarditis has been described after smallpox vaccination using replication-competent vaccinia strains.

Methods

We examined the incidence of new electrocardiogram (ECG) abnormalities and evaluated the safety and immunogenicity related to vaccination. Volunteer subjects (n=90) aged 18 to 32 years were enrolled in a National Institutes of Health-sponsored phase I smallpox vaccination trial (Division of Microbiology and Infectious Diseases 02-017) and observed over a 26-week period after 2 injections of IMVAMUNE, Modified Vaccinia Ankara vaccine (Bavarian Nordic A/S, Copenhagen, DK), followed by scarification with Dryvax (Wyeth Laboratories, Marietta, Penn). Diagnostic computer-derived ECG statements were available to the clinical study team and compared with those of a board-certified cardiologist who independently read the ECG tracings.

Results

Serial ECG tracings available for 89 of the subjects revealed new ST-segment abnormalities in 2.2% and new T-wave abnormalities in 15.7%; the majority (71.4%) resolved on subsequent tracings. Cardiologist over-read of computer statements resulted in frequent changes in readings, particularly negation of cardiac arrhythmias. A cardiology consultation was requested in 17 subjects for nonspecific cardiac symptoms or new abnormal ECG findings. Echocardiograms were performed in 12 of the 17 subjects and were normal except for 1 subject with possible myopericarditis after receiving Dryvax.

Conclusion

New minor ECG abnormalities are common in apparently young healthy volunteers considered for smallpox vaccination trials. Cardiologist over-read of computer-generated ECG statements in vaccine trials using ECG as a screening tool for safety can reduce false-positive computer-determined ECG diagnoses and the need for inappropriate cardiology referral and additional noninvasive testing.

El texto completo de este artículo está disponible en PDF.

Keywords : Early repolarization, Electrocardiography, Modified Vaccinia Ankara, Myopericarditis, Smallpox vaccine


Esquema


 Funding: Supported by National Institutes of Health N01-AI-25464, Bethesda, Maryland.


© 2009  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 122 - N° 1

P. 79-84 - janvier 2009 Regresar al número
Artículo precedente Artículo precedente
  • Relationship of Ethnic Origin, Gender, and Age to Blood Creatine Kinase Levels
  • Ryan C. Neal, Keith C. Ferdinand, Joseph Yčas, Elinor Miller
| Artículo siguiente Artículo siguiente
  • Diagnosis and Treatment of Pheochromocytoma in an Academic Hospital from 1997 to 2007
  • Run Yu, Nicholas N. Nissen, Preeti Chopra, Deepti Dhall, Edward Phillips, Meng Wei

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.